Agenda oficial
Programa científico
26–29 de abril de 2027 · Hospedería Fonseca, Salamanca. 4 jornadas y 40 ponencias orales.
Día 1 de 4
Lunes 26 de abril
4 de 4 actividades
- 13:00 - 18:30 Registration Desk Open Registro
- 16:00 Plenaria
- 16:15 - 17:15 Keynote
Keynote Lecture
James Gulley · National Institutes of Health (NIH)
“NeoAdjuvant Trial Design”
- 17:15 - 21:00 Social y pósteres
Reception and Poster Session
No hay resultados en esta jornada
Prueba con otro filtro o revisa otro día.
Día 2 de 4
Martes 27 de abril
12 de 12 actividades
- 07:30 - 18:30 Registration Desk Open Registro
- 07:30 - 08:30 Welcome & Delegate Registration with Breakfast, Coffee & Tea Restauración
- 08:30 - 09:30 Keynote
Keynote Lecture
Nathalie Agar · Harvard University
“Spatial imaging, mass spec imaging, and metabolomics”
- 09:30 - 10:30 Sesión científica
Session #1: Clinical Trials I (Part 1)
Moderan: Nino Chiocca and Alan Melcher
- 09:30 - 09:50
Thomas Heineman · Oncolytics Biotech
Clinical Efficacy and Future Development of Pelareorep: A Novel Reovirus with Demonstrated Activity in Multiple Gastrointestinal Cancers
- 09:55 - 10:15
Akseli Hemminki · TILT
Which is more effective clinically, intravenous or intratumoral delivery? Data from circa 100 patients treated with oncolytic adenovirus TILT-123
- 10:20 - 10:30
Shruthi Naik · Mayo Clinic
Combination systemic oncolytic immunotherapy in patients with advanced neuroendocrine carcinoma
- 09:30 - 09:50
- 10:35 - 10:50 Industria
Industry Presentation: A Revolutionary Cell Culture Format
XDemics Inc
- 10:50 - 11:15 Morning Coffee Break Pausa café
- 11:15 - 12:50 Sesión científica
Session #1: Clinical Trials I (Part 2)
Moderan: Nino Chiocca and Alan Melcher
- 11:15 - 11:35
James Burke · Kalivir
Cretostimogene (aka CG0070) for non-muscle invasive bladder cancer – a clinical update
- 11:40 - 12:00
William Jia · Virogin
Oncolytic virotherapy: A potential cornerstone for all IO modalities
- 12:05 - 12:25
Francesca Barone · Candel
CAN-2409: locally delivered viral immunotherapy for solid tumors
- 12:30 - 12:50
Evanthia Galanis · Mayo Clinic
Phase I/II trial of measles virus infected adipose tissue derived mesenchymal stem cells in patients with recurrent ovarian cancer
- 11:15 - 11:35
- 12:55 - 14:00 Lunch (Provided) Restauración
- 14:00 - 15:20 Sesión científica
Session #2: Combination Therapies
Moderan: Stephen Russell and Sam Rabkin
- 14:00 - 14:20
Kah-Whye Peng · Vyriad
A Phase 1 Clinical Trial to Evaluate Intravenous VSV-IFNß-NIS in Combination with Cemiplimab and Ipilimumab for Relapsed Peripheral T-Cell Lymphoma
- 14:25 - 14:35
Samuel Rabkin · Harvard
Oncolytic HSV Synergizes with DNA-PKcs Inhibition to Treat Glioblastoma
- 14:40 - 14:50
Richard Vile · Mayo Clinic
Oncolytic Virus-Specific T Cell Receptor Activation Enhances CAR T Cell Potency, Persistence and Anti-Tumour Efficacy
- 14:55 - 15:05
Candelaria Gomez-Manzano · MD Anderson
Epigenetic Modulation of P300/CBP Boosts Delta-24-RGD-Induced Immune Cell Recruitment in Diffuse Midline Glioma
- 15:10 - 15:20
Tomoko Fujiyuki · Teikyo University
Immune responses elicited by rMV-SLAMblind oncolytic therapy exert a synergistic effect on the cancer therapy
- 14:00 - 14:20
- 15:20 - 16:00 Afternoon Coffee Break Pausa café
- 16:00 - 17:30 Sesión científica
Session #3: Mechanism of Action
Moderan: Brian Lichty and Tommy Alain
- 16:00 - 16:20
Chae-ok Yun · GeneMedicine
Intranasal Nanoplatform and Potent Oncolytic Adenovirus Therapy for Glioblastoma
- 16:25 - 16:35
Frederic Tangy · Oncovita
Disabling a key viral innate immunity antagonist converts measles vaccine into RIG-I–driven cancer immunotherapy
- 16:40 - 16:50
Leandro Silva da Costa · Aarhus University
Oncolytic VSVdeltaM51 Activates NLRP1 Inflammasome Signaling While Wild-Type VSV Evades Innate Restriction
- 16:55 - 17:05
Bangxing Hong · Augusta University
Beta-blocker mitigates perivascular macrophage mediated immunosuppression during oncolytic herpes virotherapy
- 17:10 - 17:20
Norimitsu Kadowaki · Kagawa University
The Abscopal Effect of Oncolytic HSV-1 Requires TLR9-Driven Plasmacytoid Dendritic Cell Activation
- 16:00 - 16:20
- 17:30 - 21:00 Social y pósteres
Poster Session, Buffet Dinner & Drinks
No hay resultados en esta jornada
Prueba con otro filtro o revisa otro día.
Día 3 de 4
Miércoles 28 de abril
9 de 9 actividades
- 08:00 - 18:30 Registration Desk Open Registro
- 08:00 - 09:00 Welcome & Delegate Registration with Breakfast, Coffee & Tea Restauración
- 09:00 - 10:15 Sesión científica
Session #4: Clinical Trials II
Moderan: Evanthia Galanis and Kah-Whye Peng
- 09:00 - 09:20
James Burke · Kalivir
VET3-TGI: Interim Phase I Clinical data in Solid Tumours
- 09:25 - 09:45
Praveen Bommareddy · Replimune
Next generation Oncolytic immunotherapy for cancer treatment
- 09:50 - 10:00
Frederick Lang · MD Anderson
Phase I Trial of Bone Marrow-Derived Mesenchymal Stem Cells Carrying Delta-24-RGD Delivered via Endovascular Selective Intra-arterial (ESIA) Infusion in Recurrent Glioma: Initial Report
- 09:00 - 09:20
- 10:15 - 10:45 Morning Coffee Break Pausa café
- 10:45 - 12:30 Sesión científica
Session #5: Novel Platforms and Payloads
Moderan: Grant McFadden and John Bell
- 10:45 - 11:05
Adam Schieferecke · Vivere
CRISPR-Guided Evolution of Improved Delivery Systems for Genetically Encoded Immunotherapies
- 11:10 - 11:30
Nanhai Chen · ViroMissile
A Systemically Deliverable Vaccinia-Based Oncolytic Virus, VIR106, Demonstrates Potent Antitumor Activity After a Single Intravenous Dose
- 11:35 - 11:55
Stephen Russell · Vyriad
Oncolytic Virotherapy Expands and Reprograms T Cells into CAR-T Cells Within the Tumor Microenvironment
- 12:00 - 12:10
Tommy Alain · CHEO
Oncolytic reovirus as an oral cancer immunotherapy
- 12:15 - 12:25
Karen Mossman · McMaster University
HLA-matched humanized mouse model to study pancreatic ductal adenocarcinoma
- 10:45 - 11:05
- 12:30 - 14:00 Lunch (Provided) Restauración
- 14:00 - 15:30 Sesión científica
Session #6: Tumour Microenvironment
Moderan: Nori Kasahara and Carolina Ilkow
- 14:00 - 14:20
Nino Chiocca · Harvard
Persistent T cell Activation and Cytotoxicity against Human Glioblastoma Following Single Oncolytic Virus Treatment
- 14:25 - 14:45
Alan Melcher · The Institute of Cancer Research
Impact of Anti-viral vs Anti-tumour CD8 response on treatment with HSV
- 14:50 - 15:00
Liang Deng · Rockefeller
Intravesical Recombinant MVA Therapy Induces Local and Systemic Antitumor Immunity and Memory in an Orthotopic Murine Bladder Cancer Model
- 15:05 - 15:15
Elizabeth Appleton · ICR UK
Intratumoural oncolytic HSV-1 reshapes the local and systemic immune landscape through CD8+ T cell reprogramming
- 15:20 - 15:30
Duong Nguyen · Calidi
A Next-Generation Systemic Platform for Tumor-Localized Expression of T-Cell Engagers and Immune Activator
- 15:35 - 15:45
Yong Tang · Guangxi Medical University Cancer Hospital
Mesenchymal Stem Cells Delivering IL-33 Oncolytic Vaccinia Virus Enhance Antitumor Effects and Overcome PD-1 Inhibitor Resistance in Bladder Cancer
- 14:00 - 14:20
- 15:45 - 19:00 Free time for Delegates Pausa café
- 19:00 - 23:30 Social y pósteres · Norðurljós Hall at Harpa Conference Centre
Official Banquet Dinner
Included for registered delegates
No hay resultados en esta jornada
Prueba con otro filtro o revisa otro día.
Día 4 de 4
Jueves 29 de abril
7 de 7 actividades
- 08:00 - 13:00 Registration Desk Open Registro
- 08:00 - 08:45 Welcome & Delegate Registration with Breakfast, Coffee & Tea Restauración
- 08:45 - 09:45 Keynote
Keynote Lecture
Klaus Pantel · Medical Center Hamburg-Eppendorf (UKE)
“Using Liquid Biopsies to Monitor Clinical Trials”
- 09:45 - 10:45 Sesión científica
Session #7: Biomarkers of Clinical Response
Moderan: Brian Lichty and Alan Melcher
- 09:45 - 10:05
Richard Trauger · Oncolytics Biotech
Innate, anti-viral and anti-tumor biomarkers associated with clinical responses to pelareorep
- 10:10 - 10:20
Juan Fueyo · MD Anderson
Integrative TCR-seq/Spatial transcriptomics studies correlate with survival in virotherapy-treated gliomas
- 10:25 - 10:35
Linus Kloker · University Hospital Tübingen
Case series: Off-label treatment with T-VEC as an additive immunovirotherapy for aggressive NUT-carcinomas
- 10:40 - 10:50
Talia Biran · Cornell
Long Term Survival with Oncolytic Viral therapy: Final results of a Phase II study of Telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma
- 09:45 - 10:05
- 10:55 - 11:20 Morning Coffee Break Pausa café
- 11:20 - 12:35 Sesión científica
Session #8: Young Investigators Talks
Moderan: Carolina Ilkow and Tommy Alain
- 11:20 - 11:30
Victor Arias · University of Helsinki
Neutralizing antibodies as biomarkers and functional effectors in TILT-123 oncolytic adenovirus therapy
- 11:35 - 11:45
Iker Ausejo Mauleon · University of Navarra
The combination of Delta-24-RGD and TIM-3 blockade enhances oncolytic virotherapy in diffuse midline glioma
- 11:50 - 12:00
Kyla Boyd · Mayo Clinic
Improved iRNA-LNP Therapeutic Performance Through 5’UTR-Restricted MicroRNA Detargeting
- 12:05 - 12:15
Tine Deconinck · KU Leuven
Comparative evaluation of oncolytic viruses reveals opposing preferences for glioblastoma subtypes
- 12:20 - 12:30
Ryo Ikushima · Kyoto Prefectural University of Medicine
A Potent and Selective PHOX2B Promoter–Driven Oncolytic Adenovirus for Targeted Neuroblastoma Therapy
- 11:20 - 11:30
- 12:35 Plenaria
Closing Remarks and Farewell
No hay resultados en esta jornada
Prueba con otro filtro o revisa otro día.